Table 4.
Recent phase II/III clinical trials of OV therapy for GBM treatment.
| Identifier | Title | Phase | Treatment approach | Patient type | Status |
|---|---|---|---|---|---|
| NCT00028158 | An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma | 1/2 | HSV G207 | Recurrent malignant glioma | Completed |
| NCT01301430 | Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. | 1/2 | ParvOryx | Recurrent or progressive GBM | Completed |
| NCT01956734 | Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent | 1 | DNX-2401 Temozolomide |
First recurrent GBM | Completed |
| NCT02197169 | A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I) | 1 | DNX-2401 IFN-γ |
rGBM or Gliosarcoma | Completed |
| NCT02062827 | A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma | 1 | M032 | Recurrent/progressive GBM multiforme, anaplastic astrocytoma, or gliosarcoma | Active |
| NCT03072134 | Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma | 1 | NSC-CRAd-S-p7 Adiation/chemotherapy |
Newly diagnosed malignant glioma | Completed |
| NCT02798406 | A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) | 2 | DNX-2401 pembrolizumab |
rGBM or Gliosarcoma | Completed |
| NCT02457845 | Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors | 1 | HSV G207 Radiotherapy |
Recurrent malignant glioma (Supratentorial) | Active |
| NCT00528684 | A Phase I/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN® for the Treatment of Patients With Histologically Confirmed Recurrent Malignant Gliomas | 1 | REOLYSIN | Recurrent malignant glioma | Completed |
Data from ClinicalTrials.gov.